Evidence map›Paper›PMID 24362944›Full record

ArticleJournal of gastroenterology2014

Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.

Hatsue Fujino, Michio Imamura, Yuko Nagaoki, Yoshiiku Kawakami, Hiromi Abe, C Nelson Hayes, Hiromi Kan, Takayuki Fukuhara, Tomoki Kobayashi, Keiichi Masaki and 20 more

Abstract readControlled Clinical Trial
PubMed Publisher
In one paragraph

Article in Journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Hepatitis C Infection in the Elderly.Digestive diseases and sciences · 2015
    Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Expression of Interferon Lambda 4 Is Associated with Reduced Proliferation and Increased Cell Death in Human Hepatic Cells.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2015
    Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 3 institutions in 1 country.

Hatsue FujinoDepartment of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Michio Imamura
Yuko Nagaoki
Yoshiiku Kawakami
Hiromi Abe
C Nelson Hayes
Hiromi Kan
Takayuki Fukuhara
Tomoki Kobayashi
Keiichi Masaki
Atsushi Ono
Takashi Nakahara
Youji Honda
Noriaki Naeshiro
Ayako Urabe
Satoe Yokoyama
Daisuke Miyaki
Eisuke Murakami
Tomokazu Kawaoka
Nobuhiko Hiraga
Masataka Tsuge
Akira Hiramatsu
Hideyuki Hyogo
Hiroshi Aikata
Shoichi Takahashi
Daiki Miki
Hidenori Ochi
Waka Ohishi
Kazuaki Chayama
Hiroshima Liver Study Group
Hiroshima University · JPRadiation Effects Research Foundation · JPRIKEN · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOlder patients with chronic hepatitis C have a lower virological response to interferon (IFN) treatment compared to younger patients. The efficacy of telaprevir (TVR) and PEG-IFN plus ribavirin combination therapy and the predictive value of recently identified IFN lambda (IFNL) 4 polymorphisms on the outcome of therapy for older patients have not been addressed.

methodsWe assessed predictive factors for sustained virological response (SVR) to triple therapy in 226 younger (≤65 years) and 87 older (>65 years) Japanese patients with chronic genotype 1 hepatitis C. IFNL4 polymorphism ss469415590 was analyzed by Invader assay.

resultsThe SVR rate for older patients was slightly lower than for younger patients (69 vs. 82%, P = 0.043). In the older group, the SVR rate for patients with the IFNL4 TT/TT genotype was significantly higher than patients with TT/ΔG or ΔG/ΔG genotypes (81.8 and 42.9%, P = 0.003). In multivariate regression analysis, rapid virological response (OR 36.601, P = 0.002) and IFNL4 TT/TT genotype (OR 19.502, P = 0.009) were identified as significant independent predictors for SVR in older patients. Treatment-related decreases in hemoglobin and increases in serum creatinine were higher in older patients than younger patients. Reduction of initial TVR dose to 1,500 mg per day alleviated these adverse events without compromising SVR rate in older patients.

conclusionsAnalysis of IFNL4 polymorphisms is a valuable predictor in older patients receiving TVR triple therapy. 1,500 mg per day is a suitable initial TVR dose for older Japanese patients.

Indexed as

AdultAgedAge FactorsAntiviral AgentsDose-Response Relationship, DrugDrug Therapy, CombinationFemaleGenotypeHepacivirusHepatitis C, ChronicHumansInterferon-alphaInterferon alpha-2Interferon LambdaInterleukinsMaleAntiviral AgentsIFNL4 protein, humanInterferon-alphaInterferon alpha-2Interferon LambdaInterleukinsOligopeptidespeginterferon alfa-2bPolyethylene GlycolsRecombinant ProteinsRibavirintelaprevir

Identifiers

PMID24362944
OpenAlexW1994851963

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.